HI
ABBV icon

Horizon Investments’s AbbVie ABBV Stock Holding History

Horizon Investments’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3M Sell
89,420
-50,221
-36% -$11.1M 0.22% 80
2025
Q4 		$31.7M Buy
139,641
+59,618
+75% +$13.6M 0.4% 40
2025
Q3 		$18.4M Buy
80,023
+24,756
+45% +$5.04M 0.24% 77
2025
Q2 		$10.2M Buy
55,267
+33,276
+151% +$6.18M 0.16% 104
2025
Q1 		$4.57M Buy
21,991
+830
+4% +$161K 0.14% 97
2024
Q4 		$3.73M Buy
21,161
+617
+3% +$113K 0.11% 112
2024
Q3 		$4.02M Buy
20,544
+8,719
+74% +$1.63M 0.11% 100
2024
Q2 		$2.01M Sell
11,825
-13,905
-54% -$2.3M 0.06% 160
2024
Q1 		$4.64M Buy
25,730
+1,080
+4% +$186K 0.12% 90
2023
Q4 		$3.78M Sell
24,650
-7,964
-24% -$1.16M 0.11% 91
2023
Q3 		$4.81M Buy
32,614
+447
+1% +$65.6K 0.15% 72
2023
Q2 		$4.29M Sell
32,167
-2,241
-7% -$329K 0.12% 73
2023
Q1 		$5.43M Buy
34,408
+6,488
+23% +$992K 0.16% 65
2022
Q4 		$4.47M Buy
27,920
+18,186
+187% +$2.79M 0.13% 78
2022
Q3 		$1.29M Sell
9,734
-46,476
-83% -$6.67M 0.04% 166
2022
Q2 		$8.53M Sell
56,210
-2,750
-5% -$420K 0.27% 39
2022
Q1 		$9.48M Buy
58,960
+25,760
+78% +$3.74M 0.27% 46
2021
Q4 		$4.45M Buy
33,200
+21,082
+174% +$2.49M 0.13% 84
2021
Q3 		$1.29M Sell
12,118
-34,990
-74% -$4M 0.03% 188
2021
Q2 		$5.25M Sell
47,108
-11,424
-20% -$1.29M 0.16% 70
2021
Q1 		$6.33M Buy
+58,532
New +$6.26M 0.23% 49
2020
Q4 		– Sell
-45,940
Closed -$3.97M – 95
2020
Q3 		$3.97M Sell
45,940
-27,842
-38% -$2.62M 0.14% 77
2020
Q2 		$7.16M Buy
73,782
+24,110
+49% +$2.12M 0.18% 61
2020
Q1 		$3.73M Buy
49,672
+30,505
+159% +$2.6M 0.18% 44
2019
Q4 		$1.7M Buy
19,167
+12,528
+189% +$1.04M 0.07% 126
2019
Q3 		$495K Buy
6,639
+638
+11% +$43.7K 0.02% 163
2019
Q2 		$436K Buy
6,001
+569
+10% +$44.7K 0.01% 281
2019
Q1 		$432K Buy
5,432
+3,214
+145% +$263K 0.02% 217
2018
Q4 		$204K Buy
+2,218
New +$195K 0.01% 195

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Horizon Investments's ABBV Position: Q1 2026 in Review

Horizon Investments reduced its AbbVie (ABBV) stake by 36% in Q1 2026, selling an estimated $11.1M and leaving 89,420 shares worth $19.3M. The position accounts for 0.22% of the portfolio, ranked #80.

Horizon Investments first reported a position in ABBV in Q4 2018 and has held it in 29 quarters since. The position peaked at $31.7M in Q4 2025. 4,087 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Horizon Investments held 89,420 shares of AbbVie worth $19.3M as of Q1 2026.
  • Horizon Investments sold 50,221 AbbVie shares in Q1 2026, an estimated $11.1M.
  • AbbVie made up 0.22% of Horizon Investments's portfolio in Q1 2026, its #80 holding.
  • Horizon Investments first reported a position in AbbVie in Q4 2018 and has held it in 29 quarters since.
  • Horizon Investments's AbbVie position peaked at $31.7M in Q4 2025.
  • 4,087 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.